Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) European vaccine manufacturer, have signed a second agreement for the exclusive bulk supply and commercialisation of the Tetanus vaccine (SPVX06). This agreement follows a similar arrangement with Bul Bio for the Tetanus diphtheria vaccine (SPVX02) in September 2022. “As a result of this strategic […]
Read More
Stablepharma Ltd is delighted to announce that Lorena Carmona-Rodiguez is joining the Science Team at our R&D Centre in Madrid, Spain. Lorena joins ‘The Fridge-free Vaccine Company’ as Senior Scientist to specifically progress our mRNA-LNP programme. Lorena has a Master’s Degree and PhD in Molecular Biosciences from the Universidad Autónoma de Madrid. She was, until […]
Read More
It is with great sadness and regret that the Board of Stablepharma has to announce the unexpected passing of Martin Powell on the 1st of May 2023. As our colleague and fellow Director, Martin was someone who made substantial contributions to the company since the early days and we will all miss his company, enthusiasm […]
Read More
Stablepharma, the Fridge-free Vaccine Company, is delighted to announce another new member to the Team. Richard Amaee joins as Programme Manager and will be responsible for the development of Stablepharma’s reformulated, fridge-free SPVX02 vaccine for Tetanus diphtheria, working closely with our Chief Scientific Officer (CSO), Dr Arcadio Garcia de Castro. “This is great news for […]
Read More
Professor Saul Faust, consultant paediatrician at University Hospital Southampton, has been recognised for his research into vaccines which helped determine how safe and effective they were before being rolled out. He was presented the accolade by the Prince of Wales last week after it was announced last year in the Queen’s Jubilee Honour’s List. Southampton […]
Read More
Stablepharma considers IPO, Series B round to bring vaccines to market – CEO 08:00 CEST, 5 April 2023 Stablepharma, a UK developer of the world’s first fridge-free vaccines, is evaluating an IPO and a financing round to bring two vaccines to market, CEO Özgür Tuncer told Mergermarket. The business will take a decision after the summer […]
Read More